These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11721891)

  • 1. Update on rilmenidine: clinical benefits.
    Reid JL
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):322S-324S. PubMed ID: 11721891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilmenidine: a clinical overview.
    Reid JL
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):106S-111S. PubMed ID: 10921529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study].
    Widimský J
    Vnitr Lek; 2002 Aug; 48(8):724-9. PubMed ID: 12425202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).
    Farsang C; Lengyel M; Borbás S; Zorándi A; Dienes BS;
    Curr Med Res Opin; 2003; 19(3):205-17. PubMed ID: 12803735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilmenidine: a novel approach to first-line treatment of hypertension.
    Laurent S; Safar M
    Am J Hypertens; 1992 Apr; 5(4 Pt 2):99S-105S. PubMed ID: 1350733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rilmenidine for arterial hypertension.
    Beau B; Mahieux F; Paraire M; Laurin S; Brisgand B; Vitou P
    Am J Cardiol; 1988 Feb; 61(7):95D-102D. PubMed ID: 2894168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1 receptors, cardiovascular function, and metabolism.
    Bousquet P
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):317S-321S. PubMed ID: 11721890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors.
    Harron DW
    Am J Hypertens; 1992 Apr; 5(4 Pt 2):91S-98S. PubMed ID: 1350732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome.
    Anichkov DA; Shostak NA; Schastnaya OV
    Curr Med Res Opin; 2005 Jan; 21(1):113-9. PubMed ID: 15881482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.
    Dupuy O; Bauduceau B; Mayaudon H
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):123S-126S. PubMed ID: 10921531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rilmenidine, a selective imidazoline I1 receptor binding ligand, in mild-to-moderate Thai hypertensive patients.
    Buranakitjaroen P; Kittipawong P; Koanantakul B; Piamsomboon C; Prasassarakich N; Silaraks S; Sukonthasarn A; Tiyapant A;
    J Med Assoc Thai; 2003 Oct; 86(10):903-10. PubMed ID: 14650701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist.
    Koldas L; Ayan F; Ikitimur B
    Jpn Heart J; 2003 Sep; 44(5):693-704. PubMed ID: 14587651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rilmenidine: a novel antihypertensive agent.
    Safar ME
    Am J Med; 1989 Sep; 87(3C):24S-29S. PubMed ID: 2571292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study.
    Meredith PA; Reid JL
    Am J Cardiovasc Drugs; 2004; 4(3):195-200. PubMed ID: 15134471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril.
    Scemama M; Février B; Beucler I; Dairou F
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S34-9. PubMed ID: 8642803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
    Widimský J; Sirotiaková J
    Curr Med Res Opin; 2006 Jul; 22(7):1287-94. PubMed ID: 16834827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imidazoline receptors and use of drug blocking receptors I1].
    Lada W
    Pol Merkur Lekarski; 1996 Aug; 1(2):124-5. PubMed ID: 9156911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.